1. "Gary Schwartz"
  2. "David Kelsen"
Formats
  1. Journal Article (45)
  2. Meeting Abstract (33)
  3. Conference Paper (1)
Groups
  1. Center for Pancreatic Cancer Research (79)
  2. Department of Medicine (79)
  3. Gastrointestinal Oncology Service (79)
  4. Solid Tumor Oncology Division (79)
  5. Biostatistics Service (17)
  6. Epidemiology and Biostatistics (17)

More Groups

People
  1. David Kelsen (79)
  2. Gary Schwartz (79)
  3. Eileen O'Reilly (29)
  4. Leonard Saltz (29)
  5. Manish Shah (22)
  6. David Ilson (20)

More People

Years
  1. 2012 (1)
  2. 2011 (1)
  3. 2010 (1)
  4. 2009 (3)
  5. 2008 (4)
  6. 2007 (3)

More Years

Publications
  1. Journal of Clinical Oncology (24)
  2. Clinical Cancer Research (10)
  3. Cancer (7)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (5)
  5. Annals of Oncology (4)
  6. Annals of Surgical Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (24)
  2. American Association for Cancer Research (15)
  3. Springer (10)
  4. Oxford University Press (7)
  5. Wiley Blackwell (7)
  6. Elsevier Inc. (6)

More Publishers

Results (79)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060)
    Meeting Abstract

    Janjigian, Y. Y.; Tang, L. H.; Shibata, S.; Kelsen, D. P.; Segal, M.; Cheng, C.; Schwartz, G. K.; Doyle, L. A.; Shah, M. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
    Journal Article

    Ilson, D. H.; Kelsen, D.; Shah, M.; Schwartz, G.; Levine, D. A.; Boyd, J.; Capanu, M.; Miron, B.; Klimstra, D.
    Cancer (2011)

    Fulltext@MSK | Save
  • A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060)
    Meeting Abstract

    Shah, M. A.; Smyth, E. C.; Shibata, S.; Yong, W.; Tang, L. H.; Janjigian, Y. Y.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase i trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    Journal Article

    Tew, W. P.; Radovich, D.; O'reilly, E.; Schwartz, G.; Schrag, D.; Saltz, L. B.; Kelsen, D. P.; Kepler, S.; Ilson, D. H.
    Investigational New Drugs (2009)

    Fulltext@MSK | Save
  • Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)
    Journal Article

    Schwartz, G. K.; Winter, K.; Minsky, B. D.; Crane, C.; Thomson, P. J.; Anne, P.; Gross, H.; Willett, C.; Kelsen, D.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase II study of flavopiridol (alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer
    Journal Article

    Carvajal, R. D.; Tse, A.; Shah, M. A.; Lefkowitz, R. A.; Gonen, M.; Gilman-Rosen, L.; Kortmansky, J.; Kelsen, D. P.; Schwartz, G. K.; O'Reilly, E. M.
    Pancreatology (2009)

    Fulltext@MSK | Save
  • A phase II study of docetaxel (D) followed by flavopiridol (F) in advanced, gemcitabine-refractory pancreatic cancer (PC)
    Meeting Abstract

    Carvajal, R. D.; Shah, M. A.; Tse, A.; Lefkowitz, R.; Kelsen, D. P.; Schwartz, G. K.; O'Reilly, E. M.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    Journal Article

    Tse, A. N.; Klimstra, D. S.; Gonen, M.; Shah, M.; Sheikh, T.; Sikorski, R.; Carvajal, R.; Mui, J.; Tipian, C.; O'reilly, E.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
    Journal Article

    Ku, G. Y.; Ilson, D. H.; Schwartz, L. H.; Capanu, M.; O'reilly, E.; Shah, M. A.; Kelsen, D. P.; Schwartz, G. K.
    Cancer Chemotherapy and Pharmacology (2008)

    Fulltext@MSK | Save
  • A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma
    Journal Article

    Duffy, A.; Kortmansky, J.; Schwartz, G. K.; Capanu, M.; Puleio, S.; Minsky, B.; Saltz, L.; Kelsen, D. P.; O'Reilly, E. M.
    Annals of Oncology (2008)

    Fulltext@MSK | Save